Loading...
•
Jun 30, 2025
Heron Therapeutics Q2 2025 Earnings Report
Heron Therapeutics reported Q2 2025 revenue of $37.2M and a net loss of $2.38M.
Key Takeaways
Heron Therapeutics posted Q2 2025 net revenue of $37.2 million, driven by growth in its Acute Care franchise. Despite strong product demand, the company reported a net loss of $2.38 million with an EPS of -$0.02. Cash, cash equivalents, and short-term investments stood at $40.6 million at quarter end.
Total net revenue reached $37.2 million, up 3.3% year-over-year.
ZYNRELEF and APONVIE sales saw significant quarterly growth of 40.4% and 141.6% year-over-year, respectively.
Net loss was $2.38 million with EPS of -$0.02.
Cash, cash equivalents, and short-term investments totaled $40.6 million.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Heron reaffirmed 2025 net revenue guidance of $153M–$163M and increased adjusted EBITDA guidance to $9M–$13M, driven by momentum in ZYNRELEF and APONVIE adoption and expanded sales efforts.
Positive Outlook
- Reaffirmed 2025 net revenue guidance of $153M–$163M.
- Increased adjusted EBITDA guidance to $9M–$13M.
- ZYNRELEF and APONVIE adoption expected to accelerate with dedicated sales teams.
- Permanent CMS J-code for ZYNRELEF effective October 1, 2025.
- Enhanced distributor incentives and commercial pull-through initiatives planned.
Challenges Ahead
- Oncology segment revenue declined year-over-year.
- SUSTOL sales dropped 43.4% year-over-year.
- Net loss in Q2 2025 despite strong revenue growth in Acute Care products.
- Wholesaler adjustment from ZYNRELEF VAN transition impacted revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...